HIV treatment cascade for older adults in rural South Africa.
africa
antiretroviral therapy
hiv
treatment
Journal
Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
01
12
2018
revised:
14
05
2019
accepted:
02
06
2019
pubmed:
28
6
2019
medline:
24
6
2020
entrez:
28
6
2019
Statut:
ppublish
Résumé
The HIV treatment cascade is a powerful framework for understanding progress from initial diagnosis to successful treatment. Data sources for cascades vary and often are based on clinical cohorts, population cohorts linked to clinics, or self-reported information. We use both biomarkers and self-reported data from a large population-based cohort of older South Africans to establish the first HIV cascade for this growing segment of the HIV-positive population and compare results using the different data sources. Data came from the Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South Africa (HAALSI) 2015 baseline survey of 5059 adults aged 40+ years. Dried blood spots (DBS) were screened for HIV, antiretroviral drugs and viral load. In-home surveys asked about HIV testing, diagnosis and antiretroviral therapy (ART) use. We calculated proportions and CIs for each stage of the cascade, conditional on attainment of the previous stage, using (1) biomarkers, (2) self-report and (3) both biomarkers and self-report, and compared with UNAIDS 90-90-90 targets. 4560 participants had DBS results, among whom 1048 (23%) screened HIV-positive and comprised the denominator for each cascade. The biomarker cascade showed 63% (95% CI 60 to 66) on ART and 72% (95% CI 69 to 76) of those on ART with viral suppression. Self-reports underestimated testing, diagnosis and ART, with only 47% (95% CI 44 to 50) of HIV-positive individuals reporting ART use. The combined cascade indicated high HIV testing (89% (95% CI 87 to 91)), but lower knowledge of HIV-positive status (71% (95% CI 68 to 74)). Older South Africans need repeated HIV testing and sustained ART to reach 90-90-90 targets. HIV cascades relying on self-reports are likely to underestimate true cascade attainment, and biomarkers provide substantial improvements to cascade estimates.
Identifiants
pubmed: 31243144
pii: sextrans-2018-053925
doi: 10.1136/sextrans-2018-053925
pmc: PMC6930968
mid: NIHMS1044840
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-276Subventions
Organisme : FIC NIH HHS
ID : D43 TW009775
Pays : United States
Organisme : Wellcome Trust
ID : 069683/Z/02/Z
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : R01 HD084233
Pays : United States
Organisme : Wellcome Trust
ID : 085477/Z/08/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 058893/Z/99/A
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI124389
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : P01 AG041710
Pays : United States
Organisme : Wellcome Trust
ID : 085477/B/08/Z
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI112339
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
BMJ Glob Health. 2016 Sep 15;1(2):e000010
pubmed: 28588933
PLoS One. 2011;6(7):e21795
pubmed: 21747959
Int J Epidemiol. 2018 Jun 1;47(3):689-690j
pubmed: 29325152
AIDS. 2012 Jul 31;26 Suppl 1:S1-5
pubmed: 22713477
AIDS. 2017 Feb 20;31(4):545-552
pubmed: 28121668
Demography. 2001 Feb;38(1):115-32
pubmed: 11227840
BMC Public Health. 2018 Mar 2;18(1):303
pubmed: 29499668
PLoS Med. 2015 Nov 24;12(11):e1001905; discussion e1001905
pubmed: 26599699
AIDS. 2012 Jul 31;26 Suppl 1:S31-7
pubmed: 22781173
Curr Opin HIV AIDS. 2013 Jan;8(1):59-64
pubmed: 23211779
AIDS Res Hum Retroviruses. 2014 Oct;30(10):949-55
pubmed: 24998881
Lancet HIV. 2017 May;4(5):e223-e230
pubmed: 28153470
J Int AIDS Soc. 2018 Oct;21(10):e25198
pubmed: 30362662
AIDS. 2016 Aug 24;30(13):2107-16
pubmed: 27163707
AIDS Care. 2016;28 Suppl 3:67-73
pubmed: 27421053
AIDS. 2014 Nov;28 Suppl 4:S453-9
pubmed: 25222641
Lancet. 2011 Apr 2;377(9772):1131-3
pubmed: 21126759
PLoS Med. 2016 Aug 09;13(8):e1002107
pubmed: 27504637
J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb;11(1):57-65
pubmed: 21951728
PLoS Med. 2017 Apr 4;14(4):e1002253
pubmed: 28376085
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):e9-e17
pubmed: 27926667
Curr Opin HIV AIDS. 2016 Jan;11(1):102-8
pubmed: 26545266
AIDS. 2012 Jul 31;26 Suppl 1:S55-63
pubmed: 22781177
Bull World Health Organ. 2010 Nov 1;88(11):847-53
pubmed: 21076566
J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):91-9
pubmed: 27082505
Lancet HIV. 2015 Sep;2(9):e368-75
pubmed: 26423550
Trop Med Int Health. 2014 Sep;19(9):1015-28
pubmed: 24976370
J Acquir Immune Defic Syndr. 2015 May 1;69(1):98-108
pubmed: 25942461
AIDS. 2011 Aug 24;25(13):1665-7
pubmed: 21681056
AIDS Care. 2013;25(9):1122-8
pubmed: 23311396